1. A method of treating a Philadelphia chromosome positive (Ph+) leukemia in a human patient suffering from Ph+ leukemia comprising the steps of:
(a) administering a predetermined fixed amount of Imatinib mesylate of between 200 and 800 mg to the human patient,
(b) collecting at least one blood sample from the patient,
(c) determining the plasma trough level (Cmin) of Imatinib mesylate,
(d) determining octamer binding protein activity, (OCT-1 Activity) in the at least one blood sample, and
(e) adjusting the dose of Imatinib mesylate applied to the individual patient in a manner that an Imatinib mesylate Cmin value is achieved in the patient of between 1000 and 3000 ngmL, if in step (c) an Imatinib mesylate Cmin value of less then 1000 ngmL is found and in step (d) an OCT-1 Activity is found below 6.0 to 10.0 ng200,000 cells.
2. The method according to claim 1 wherein in step (a) a daily dose of 400 mg of Imatinib mesylate is administered daily.
3. A method of treating chronic myeloid leukemia (CML) in a human patient suffering from CML comprising the steps of:
(a) administering a predetermined fixed amount of Imatinib mesylate of between 200 and 800 mg to the human patient,
(b) collecting at least one blood sample from the patient,
(c) determining the plasma trough level (Cmin) of Imatinib mesylate,
(d) determining octamer binding protein activity, (OCT-1 Activity) in the at least one blood sample, and
(e) adjusting the dose of Imatinib mesylate applied to the individual patient in a manner that an Imatinib mesylate Cmin value is achieved in the patient of between 1000 and 3000 ngmL, if in step (c) an Imatinib mesylate Cmin value of less than 1000 ngmL is found and in step (d) an OCT-1 Activity is found below 6.0 to 10.0 ng200,000 cells.
4. The method according to claim 3 wherein in step (a) a daily dose of 400 mg of Imatinib mesylate is administered daily.
5. A method of treating Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in a human patient suffering from Ph+ ALL comprising the steps of:
(a) administering a predetermined fixed amount of Imatinib mesylate of between 200 and 800 mg to the human patient,
(b) collecting at least one blood sample from the patient,
(c) determining the plasma trough level (Cmin) of Imatinib mesylate,
(d) determining octamer binding protein activity, (OCT-1 Activity) in the at least one blood sample, and
(e) adjusting the dose of Imatinib mesylate applied to the individual patient in a manner that an Imatinib mesylate Cmin value is achieved in the patient of between 1000 and 3000 ngmL, if in step (c) an Imatinib mesylate Cmin value of less than 1000 ngmL is found and in step (d) an OCT-1 Activity is found below 6.0 to 10.0 ng200,000 cells.
6. The method according to claim 5 wherein in step (a) a daily dose of 400 mg of Imatinib mesylate is administered daily.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound represented by formula (56),
2. A light-emitting element comprising a layer provided between a pair of electrodes, wherein the layer includes the compound according to claim 1.
3. A light-emitting element comprising a light-emitting layer provided between a pair of electrodes, wherein the light-emitting layer includes the compound according to claim 1.
4. A light-emitting element comprising:
an anode;
a hole transporting layer over the anode;
a light-emitting layer over the hole transporting layer; and
a cathode over the light-emitting layer,
wherein the hole transporting layer includes the compound according to claim 1.
5. A light-emitting element comprising:
an anode;
a hole injecting layer over the anode;
a light-emitting layer over the hole injecting layer; and
a cathode over the light-emitting layer,
wherein the hole injecting layer includes the compound according to claim 1.
6. A light-emitting device comprising the light-emitting element according to claim 2.
7. A lighting installation comprising the light-emitting element according to claim 2.
8. An electronic apparatus comprising the light-emitting element according to claim 2, wherein the electronic apparatus is one selected from the group consisting of a camera, a goggle type display, a navigation system, a sound reproduction device, a personal computer, a game machine, a portable information terminal, and an image reproduction device equipped with a recording medium.
9. A compound represented by formula (61),
10. A light-emitting element comprising a layer provided between a pair of electrodes, wherein the layer includes the compound according to claim 9.
11. A light-emitting element comprising a light-emitting layer provided between a pair of electrodes, wherein the light-emitting layer includes the compound according to claim 9.
12. A light-emitting element comprising:
an anode;
a hole transporting layer over the anode;
a light-emitting layer over the hole transporting layer; and
a cathode over the light-emitting layer,
wherein the hole transporting layer includes the compound according to claim 9.
13. A light-emitting element comprising:
an anode;
a hole injecting layer over the anode;
a light-emitting layer over the hole injecting layer; and
a cathode over the light-emitting layer,
wherein the hole injecting layer includes the compound according to claim 9.
14. A light-emitting device comprising the light-emitting element according to claim 10.
15. A lighting installation comprising the light-emitting element according to claim 10.
16. An electronic apparatus comprising the light-emitting element according to claim 10, wherein the electronic apparatus is one selected from the group consisting of a camera, a goggle type display, a navigation system, a sound reproduction device, a personal computer, a game machine, a portable information terminal, and an image reproduction device equipped with a recording medium.